Last update 20 Mar 2025

IMT-009

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Rezorstobart, IMT 009, IMT-009
Target
Action
inhibitors
Mechanism
CD161 inhibitors(killer cell lectin like receptor B1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
United States
28 Nov 2022
Burkitt LymphomaPhase 2
United States
28 Nov 2022
Cutaneous Squamous Cell CarcinomaPhase 2
United States
28 Nov 2022
Diffuse Large B-Cell LymphomaPhase 2
United States
28 Nov 2022
Esophageal CarcinomaPhase 2
United States
28 Nov 2022
Follicular LymphomaPhase 2
United States
28 Nov 2022
Hodgkin's LymphomaPhase 2
United States
28 Nov 2022
Hormone Receptor Positive Breast AdenocarcinomaPhase 2
United States
28 Nov 2022
Microsatellite instability-high colorectal cancerPhase 2
United States
28 Nov 2022
Microsatellite Stable Colorectal CarcinomaPhase 2
United States
28 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free